Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
J Cell Mol Med ; 24(21): 12869-12872, 2020 11.
Article in English | MEDLINE | ID: covidwho-863121


Considering lack of target-specific antiviral treatment and vaccination for COVID-19, it is absolutely exigent to have an effective therapeutic modality to reduce hospitalization and mortality rate as well as to improve COVID-19-infected patient outcomes. In a follow-up study to our recent findings indicating the potential of Cannabidiol (CBD) in the treatment of acute respiratory distress syndrome (ARDS), here we show for the first time that CBD may ameliorate the symptoms of ARDS through up-regulation of apelin, a peptide with significant role in the central and peripheral regulation of immunity, CNS, metabolic and cardiovascular system. By administering intranasal Poly (I:C), a synthetic viral dsRNA, while we were able to mimic the symptoms of ARDS in a murine model, interestingly, there was a significant decrease in the expression of apelin in both blood and lung tissues. CBD treatment was able to reverse the symptoms of ARDS towards a normal level. Importantly, CBD treatment increased the apelin expression significantly, suggesting a potential crosstalk between apelinergic system and CBD may be the therapeutic target in the treatment of inflammatory diseases such as COVID-19 and many other pathologic conditions.

Apelin/metabolism , Cannabidiol/pharmacology , Respiratory Distress Syndrome/drug therapy , Administration, Intranasal , Animals , Lung/drug effects , Lung/pathology , Male , Mice, Inbred C57BL , Poly I-C/toxicity , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/metabolism , Respiratory Distress Syndrome/pathology
J Mol Cell Cardiol ; 145: 84-87, 2020 08.
Article in English | MEDLINE | ID: covidwho-602090


We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio.

Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Apelin Receptors/therapeutic use , Apelin/therapeutic use , Betacoronavirus/metabolism , Coronavirus Infections/drug therapy , Peptidyl-Dipeptidase A/metabolism , Pneumonia, Viral/drug therapy , Angiotensin I/metabolism , Angiotensin II/biosynthesis , Angiotensin II/blood , Angiotensin-Converting Enzyme 2 , Animals , Apelin/metabolism , Apelin Receptors/agonists , Apelin Receptors/metabolism , COVID-19 , Coronavirus Infections/virology , Drug Repositioning/methods , Humans , Mice , Pandemics , Peptide Fragments/metabolism , Pneumonia, Viral/virology , Receptor, Angiotensin, Type 1/metabolism , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/immunology , SARS-CoV-2